Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Liu, Li ^a   Beck, Haley ^a   Wang, Xiaolei ^c   Hsieh, Hsing Pang ^b   Mason, Ralph P ^a   Liu, Xinli ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 3 (3',4' ,5' TRIMETHOXY BENZOYL) 1H INDOLE; ANTINEOPLASTIC AGENT; BPR 0L075; CD31 ANTIGEN; HOE 33342; LUCIFERASE; LUCIFERIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CELL DISRUPTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG ELIMINATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; IN VITRO STUDY; MAMMARY FAT PAD; MAMMARY GLAND; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR BLOOD FLOW; TUMOR CELL CULTURE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, NUDE; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865281105     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043314     Document Type: Article

References (36)

1. Heath VL, Bicknell R, (2009) Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6: 395-404.
2. Tozer GM, Kanthou C, Parkins CS, Hill SA, (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21-38.
3. Chaplin DJ, Dougherty GJ, (1999) Tumour vasculature as a target for cancer therapy. Br J Cancer 80 Suppl 1: 57-64.
4. Denekamp J, (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9: 267-282.
5. Kerbel RS, (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
6. Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, et al. (2008) Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 81 Spec No 1: S12-20.
7. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, et al. (2004) BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 64: 4621-4628.
8. Chen CP, Hu CB, Yeh KC, Song JS, Yeh TK, et al. (2010) Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Res 30: 2813-2822.
9. Schwartz EL, (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15: 2594-2601.
10. Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG, (2011) A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr Biol (Camb) 3 (4) (): 375-387.
11. Zhao D, Richer E, Antich PP, Mason RP, (2008) Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging (BLI) and confirmed by magnetic resonance imaging (MRI). FASEB J 22: 2445-2451.
12. Denekamp J, (1984) Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23: 217-225.
13. Denekamp J, Hobson B, (1982) Endothelial-cell proliferation in experimental tumours. Br J Cancer 46: 711-720.
14. Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK, (2000) Formation of endothelial cell networks. Nature 405: 139-141.
15. Jain RK, (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
16. Siemann DW, (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 37: 63-74.
17. McKeage MJ, Baguley BC, (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116: 1859-1871.
18. Sun A, Hou L, Prugpichailers T, Dunkel J, Kalani MA, et al. Firefly Luciferase-Based Dynamic Bioluminescence Imaging: A Noninvasive Technique to Assess Tumor Angiogenesis. Neurosurgery 66: 751-757.
19. Zhao D, Jiang L, Hahn EW, Mason RP, (2005) Tumor physiological response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 62: 872-880.
20. Masunaga S, Nagasawa H, Nagata K, Suzuki M, Uto Y, et al. (2007) Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells. J Cancer Res Clin Oncol 133: 47-55.
21. Horsman MR, Siemann DW, (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520-11539.
22. Cai W, Gambhir SS, Chen X (2008) Chapter 7 Molecular Imaging of Tumor Vasculature. Methods in Enzymology: Academic Press. pp. 141-176.
23. Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, et al. (2004) Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Molecular Imaging 3: 117-124.
24. Maye P, Fu Y, Butler DL, Chokalingam K, Liu Y, et al. (2011) Generation and characterization of Col10a1-mcherry reporter mice. Genesis 49: 410-418.
25. Siemann DW, (2010) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev.
26. Siemann DW, Horsman MR, (2009) Vascular targeted therapies in oncology. Cell Tissue Res 335: 241-248.
27. Tozer GM, Kanthou C, Baguley BC, (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
28. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ, (2002) ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54: 1497-1502.
29. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, et al. (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253.
30. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, et al. (2001) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21: 93-102.
31. Nicholson B, Lloyd GK, Miller BR, Palladino MA, Kiso Y, et al. (2006) NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 17: 25-31.
32. Liou JP, Chang CW, Song JS, Yang YN, Yeh CF, et al. (2002) Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J Med Chem 45: 2556-2562.
33. Liu L, Mason RP, (2010) Imaging beta-galactosidase activity in human tumor xenografts and transgenic mice using a chemiluminescent substrate. PLoS One 5: e12024.
34. Contero A, Richer E, Gondim A, Mason RP, (2009) High-throughput quantitative bioluminescence imaging for assessing tumor burden. Methods Mol Biol 574: 37-45.
35. Brown KJ, Maynes SF, Bezos A, Maguire DJ, Ford MD, et al. (1996) A novel in vitro assay for human angiogenesis. Lab Invest 75: 539-555.
36. Nicosia RF, Lin YJ, Hazelton D, Qian X, (1997) Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am J Pathol 151: 1379-1386.